Neuroimaging and CSF Biomarker RFP

The Alzheimer's Drug Discovery Foundation's Neuroimaging and CSF Biomarker RFP supports biomarker work for Alzheimer's disease and related dementias. It sits inside ADDF's wider mission to accelerate drugs that prevent, treat, and cure the disease, and it reflects the foundation's venture-philanthropy model rather than a conventional unrestricted grant line. The program is one of ADDF's recurring annual calls alongside prevention and therapeutics funding. The route uses grant funding, is open globally, and accepts applications from for-profit companies, nonprofits, universities, and research organizations. Individuals are not eligible. The award cap is $600,000, and ADDF treats the support as direct-cost funding with a one-year term and possible follow-on support. That makes the program relevant to teams that need focused capital for a defined biomarker milestone. The best fit is a project that can improve diagnosis, imaging, or trial design with a credible translational path. ADDF expects milestone-driven work and a strong scientific and business case, so the route is strongest for assays, imaging tools, or cerebrospinal-fluid biomarkers that can change how Alzheimer's research is run. For applicants, the program favors evidence of technical progress over broad exploratory claims.

Each grant below is a distinct funding opportunity with its own eligibility, scope, and deliverables.